On Tuesday, Shares of Bristol-Myers Squibb Co (NYSE:BMY), gained 2.98% to $59.01.
Bristol-Myers Squibb Company, declared updated results from the Opdivo (nivolumab)+Yervoy (ipilimumab) arms in CheckMate -012, a multi-arm Phase 1b trial evaluating Opdivo in patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC). In this study, Opdivo was administered as monotherapy or as part of a combination with other agents, counting Yervoy, at different doses and plans. Results from other cohorts in CheckMate -012 have been formerly unstated. These updated results comprise findings from the administration of four new dosing plans of Opdivo+Yervoy (n=148), which resulted in confirmed objective response rates (ORR) ranging from 13% to 39% depending on the administered regimen. Median duration of response was not reached in any of these arms with a median follow-up of 6.2 months to 16.6 months, and median progression-free survival (PFS) ranged from 4.9 months to 10.6 months.
The types of treatment-related serious adverse events (SAEs) stated in these cohorts for CheckMate -012 were consistent with other formerly-stated Opdivo+Yervoy cohorts of this trial. The new dosing plans in this study resulted in less toxicity than formerly-stated dosing plans, and were characterized by low frequency of treatment-related adverse events (AEs) leading to discontinuation (3% to 10%) and no treatment-related deaths. These data will be presented recently at the 16th World Conference on Lung Cancer (WCLC) (Abstract #786).
“Clinical results from Opdivo+Yervoy have already been stated in formerly untreated metastatic melanoma, showing the potential of dual immune checkpoint blockade targeting both PD-1 and CTLA-4,” said Naiyer Rizvi, M.D., director of Thoracic Oncology and Immunotherapeutics for the Division of Hematology and Oncology at Columbia University Medical Center. “The preliminary results from this trial in advanced non-small cell lung cancer similarly push the envelope of benefit with an immunotherapy combination strategy in the first-line treatment of advanced non-small cell lung cancer which warrants further studies.”
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.
Shares of Home Depot Inc (NYSE:HD), inclined 1.73% to $116.40, during its last trading session.
The Home Depot Canada Foundation’s month-long Celebration of Service campaign kicks-off recently, with our associate-led volunteer force “Team Depot” taking on renovation projects that assist local youth-serving organizations provides safe and stable housing, and supportive services for homeless youth.
“Giving back is a core value at The Home Depot Canada and a passion of our associates,” said Bill Lennie, chair, board of directors, The Home Depot Canada Foundation and president, The Home Depot Canada. “We are committed to assisting end youth homelessness in Canada and the contributions of our Team Depot volunteers make a substantial and lasting change for homeless youth in Canada.”
As part of the Foundation’s three-year, $10-million pledge to assist end youth homelessness in Canada, Team Depot volunteers partner with local youth-serving organizations throughout the month of September, taking on more than 100 renovation projects across the country. Projects such as installing a new kitchen, painting and refreshing common living areas and planting gardens and green spaces assist these facilities feel more like home, and supports local youth-serving organizations as they provide much-needed life skills development and job training for homeless youth.
The Home Depot, Inc. operates as a home improvement retailer. It operates The Home Depot stores that sell various building materials, home improvement products, and lawn and garden products, in addition to provide installation, home maintenance, and professional service programs to do-it-yourself, do-it-for-me, and professional customers.
Finally, Exelon Corporation (NYSE:EXC), ended its last trade with 1.92% gain, and closed at $30.29.
Exelon Corporation and Pepco Holdings Inc., issued the following statement in response to the Public Service Commission of the District of Columbia’s order on the companies’ projected merger.
“We have now received the Commission’s order, and we remain convinced the decision fails to recognize the substantial immediate and long-term benefits of our merger proposal to citizens, businesses and communities in the District of Columbia. We believe our merger proposal is in the public interest, and we will continue working to complete the merger, which all other jurisdictions have approved. Not concluding our merger would deny customers in the District of Columbia – in addition to Delaware, Maryland and New Jersey – hundreds of millions of dollars in direct financial benefits, improved reliability and storm response, renewable energy projects, and commitments that will preserve their local utility’s role as a strong community partner and contributor to economic growth. We want to deliver these benefits to customers and will strive to make that happen.”
Exelon Corporation, a utility services holding company, engages in the energy generation and delivery businesses in the United States. It owns electric generating facilities, such as nuclear, fossil, and hydroelectric generation facilities, in addition to wind and solar photovoltaic facilities.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
